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Silencing those genes that are overexpressed in cancer and contribute to the survival and progression of tumour cells is the aim of
several researches. Cyclooxygenase-2 (COX-2) is one of the most intensively studied genes since it is overexpressed in most
tumours, mainly in colon cancer. The use of specific COX-2 inhibitors to treat colon cancer has generated great enthusiasm. Yet, the
side effects of some inhibitors emerging during long-term treatment have caused much concern. Genes silencing by RNA interference
(RNAi) has led to new directions in the field of experimental oncology. In this study, we detected sequences directed against COX-2
mRNA, that potently downregulate COX-2 gene expression and inhibit phorbol 12-myristate 13-acetate-induced angiogenesis in
vitro in a specific, nontoxic manner. Moreover, we found that the insertion of a specific cassette carrying anti-COX-2 short hairpin
RNA sequence into a viral vector (pSUPER.retro) greatly increased silencing potency in a colon cancer cell line (HT29) without
activating any interferon response. Phenotypically, COX-2 deficient HT29 cells showed a significant impairment of their in vitro
malignant behaviour. Thus, the retroviral approach enhancing COX-2 knockdown, mediated by RNAi, proved to be an useful tool to
better understand the role of COX-2 in colon cancer. Furthermore, the higher infection efficiency we observed in tumour cells, if
compared to normal endothelial cells, may disclose the possibility to specifically treat tumour cells without impairing endothelial
COX-2 activity.
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The pharmacological approach to cancer treatment (chemo-
therapy) is often hindered by the lack of specificity and by acquired
cancer cells drug resistance caused by overexpressed P-glyco-
protein family proteins, which carry drugs out of cells. The
advancement in the field of RNA interference (RNAi) has opened
up a completely new strategy to silence genes involved in tumour
progression and to downregulate genes coding for P-glycoproteins
in a high specific manner (Meister and Tuschl, 2004).
The idea of silencing those genes which are overexpressed in
malignant cells is, of course, not new. In the past few years, several
attempts to obtain specific knockdown have been performed by
using stabilised antisense oligonucleotides and ribozymes (Zang
et al, 2004). Even though some success has been reported, failure
of most of clinical trials has been attributed to the assumption that
in vivo delivery is critical, owing to the toxicity and instability of
molecules used (Mello and Conte, 2004). Several reports now
indicate that these problems have been overcome by the use of
RNAi (Meister and Tuschl, 2004).
RNAi is considered a form of post-transcriptional gene
silencing, a phenomenon first described in plants, nematodes,
protozoan, invertebrate species and only recently found also in
mammalians. Observations in Caenorhabditis elegans disclosed the
remarkable capacity of double-stranded RNA molecules (dsRNA)
to specifically and potently disrupt the expression of genes
containing sequences homologous to the dsRNA. The mechanism
involves the inhibition of translation and the enzymatic degrada-
tion of target mRNAs. Fire et al (1998) argued that since few
molecules of injected dsRNA were required to affect a specific
mRNA expression, a catalytic amplification component was
involved. The amplification process has been at least partially
explained by the discovery of the dsRNA enzymatic conversion
into 21–25 nt oligoribonucleotides. The 21–25 nt oligoribo-
nucleotides, also called small interfering RNAs (siRNAs), may act
on mRNA targets as antisense oligonucleotides.
Synthetic siRNAs appeared as an important research tool for
understanding the function of a gene by silencing its expression
when Elbashir et al (2001a) reported that gene expression in
mammalian cell lines can be effectively silenced by transfecting
cells with synthetic siRNAs. The prospect of using siRNAs as
potent and specific inhibitors to any target gene provides a new
therapeutical approach for many untreatable diseases, such as viral
infections, neurodegenerative diseases and cancer.
At this time, it is widely accepted that in mammalians, as in
other organisms, physiological silencing mechanisms are based on
RNAi mediated by specific dsRNA structures, called microRNAs
(miRNAs). It has been recently demonstrated that the processing
of short hairpin RNA structures (shRNAs) overlaps the cellular
pathways in which miRNAs are involved (Bartel, 2004). This
further strengthened the concept that the use of siRNAs is
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sphysiologically relevant in diseases treatment (Bartel, 2004). It has
also been proposed that the overexpression of genes, like
cyclooxygenase-2 (COX-2), in cancer cells (Gupta and Dubois,
2001; Romano and Claria, 2003; Tuynman et al, 2004) may be due
to the disruption of a control network in which relevant microRNA
genes are implicated (Michael et al, 2003; Bartel, 2004; He et al,
2005; Lu et al, 2005).
The field of COX inhibitors has a record of continuous progress
starting from the introduction of aspirin in 1898. A large group of
nonsteroidal anti-inflammatory drugs (NSAIDs) inhibiting both
COX-1 and COX-2 isoforms followed. Only recently selective COX-
2 inhibitors (Coxibs) have been developed (Flower, 2003). Here, we
highlight a new strategy to inhibit COX-2 activity, focusing on the
role of COX-2 in angiogenesis and in colorectal cancer (CRC).
Several studies reported the relevant role of COX-2 in tumour
angiogenesis (Spisni and Tomasi, 1997; In ˜iguez et al, 2003). It has
been observed that blood vessels localised in proximity of tumours
express high levels of COX-2 whereas normal vasculature does not
(Leahy et al, 2002). In advanced CRC tissues, high COX-2 levels
seem to promote cells invasion, tumour growth and metastasisa-
tion (Yamauchi et al, 2002). To this regard, aim of this study was to
achieve a significant and specific downregulation of COX-2
expression by using RNAi mechanism. We found specific siRNAs
molecules capable of blocking angiogenesis mediated by COX-2
overexpression in human umbilical rein endothelial cells (HUVEC)
with a mechanism that does not induce, at low concentrations, the
interferon system activation. In order to obtain a stable silencing
of COX-2 gene, we also developed a retroviral vector-based
approach, failing to infect HUVE cells, but capable of infecting to a
high degree two human colorectal cancer cell lines (HT29 and
HCA7). The constitutive expression of endogenous anti-COX-2
shRNAs did not trigger any interferon system response. However,
the specific and long-lasting knockdown of COX-2 in HT29 cells
strongly affected their in vitro migratory ability and their
anchorage-independent growth in soft agar. Thus, this anti-COX-
2 expressing vector may be a valuable tool to control the role of
COX-2 expression in cancer (particularly in CRC) opening the way
to specific trials in vivo.
MATERIALS AND METHODS
Cell lines
Human endothelial cells were isolated from freshly collected
umbilical cords. Cells were grown in M199 medium supplemented
with 20% foetal calf serum (FCS), 100mgml
 1 ECGS, 100mgml
 1
heparin, 2mML -glutamine and antibiotics (penicillin 100Uml
 1
and streptomycin 100mgml
 1), as previously described (Spisni
et al, 1995). Cells were maintained at 371Ci n5 %C O 2 and used for
experiments between third and fifth passage. HT29 human colon
cancer cells were obtained from American Type Culture Collection
(Manassas, VA, USA). HCA7 cells were obtained from European
Collection of Cell Cultures (ECACC; Salisbury, Wiltshire, UK).
Both HT29 and HCA7 cells were cultured at 371C in 5% CO2 in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% heat-inactivated FCS, 2mML -glutamine, penicillin 100Uml
 1
and streptomycin 100mgml
 1. Foetal calf serum and DMEM were
purchased from Cambrex Biowittaker, USA. All the other reagents
were purchased from Sigma (Sigma Chemical, St Louis, USA).
Synthetic siRNAs design
Four different siRNAs against COX-2 mRNA were designed as
suggested by Elbashir et al (2002) and chemically synthesised
(PROLIGO Primers and Probes, USA). The identified target
sequences on COX-2 mRNA (NM000963) were respectively: bases
290–310 (siRNA-A, 50aaactgctcaacaccggaatt30), bases 291–311
(siRNA-B, 50aactgctcaacaccggaattt30), bases 1020–1040 (siRNA-C,
50aacagagtatgcgatgtgctt30) and bases 1429–1449 (siRNA-D, 30aagta
tcacaggcttccattg50). We also used a scrambled siRNA (Ambion,
USA) as a negative control, with no significant homology to any
known gene sequences in human, mouse and rat genome. All siRNA
sequences were controlled for their specificity by using BLAST
database and did not show any homology to other human gene.
siRNAs transfection
Human endothelial cells were seeded in 25cm
2 flasks
(150000cellsflask
 1) and grown up to 50% confluence. After
24h, cells were transfected with siRNAs by using Oligofectamine
reagent (Invitrogen, USA) according to the manufacturer’s
instructions. Briefly, each siRNA (400 fmoles) was diluted in
350ml of serum-free medium. For each flask, 10ml of Oligofecta-
mine reagent was incubated with 40ml of serum-free medium for
10min at room temperature. Oligofectamine solution (50ml) was
added to diluted siRNAs. After incubation for 20min at room
temperature, siRNAs–Oligofectamine complexes were added to
flasks containing 1.6ml of serum-free medium, resulting in 2ml of
total transfection volume and in a siRNA final concentration of
200pM. After 4h of incubation at 371C, 3ml of complete medium
containing FCS and phorbol 12-myristate 13-acetate (PMA) was
added (final concentration: 10% serum and 40nM PMA).
Western blot
Cells were scraped and lysed in lysis buffer (50mM Tris-HCl, pH
7.5, 2mM EDTA, 100mM NaCl, 1% Triton X-100 and protease
inhibitors mixture), additionated with 5mM NaF, 1mM Na3VO4,
10mM b-glycerolphosphate, for the phospho-STAT-1 immuno-
blotting experiments. Cell lysates were incubated 1h on ice and
centrifuged at 12000g to collect supernatants. Protein concentra-
tion in supernatants was evaluated by using the Lowry method.
After addition of SDS–PAGE sample buffer and boiling, 40mgo f
denatured proteins were separated in 12% SDS–PAGE and then
transferred to nitrocellulose papers. After the blotting, nitrocellu-
lose papers were incubated with specific antibodies. The primary
antibodies used were: polyclonal anti-COX-2 (Cayman Chemicals,
USA), anti-phospho-STAT-1(Tyr701) (Cell Signaling, USA) and
anti-b-actin (Sigma, USA); monoclonal anti-COX-1 (Cayman
Chemicals, USA) and anti-STAT-1 p84/p91 (Santa Cruz Biotech-
nology, USA). Secondary antibodies (HRP conjugated) were
purchased from Santa Cruz Biotechnology, USA. Immunolabelling
was visualised by using the ECL procedure (Amersham Bio-
sciences, USA). Bands were quantified by using a densitometric
image analysis software (Image Master VDS, Pharmacia Biotech,
Uppsala, Sweden). Normalisation was made against b-actin
expression.
Determination of COX-2 activity
Conditioned media from HUVE cells were collected 48h after
transfection with siRNAs and stored at  801C. Cyclooxygenase-2
enzymatic activity was evaluated by measuring the 6-keto-PGF1a
release in conditioned media by using an ELISA assay (Assay
Designs, USA), as previously described (Spisni et al, 2003). 6-keto-
PGF1a production was then related to the protein concentration in
cell lysates. PGE2 levels in HT29 culture media were evaluated by
using an ELISA assay (Cayman Chemicals, USA) and related to the
protein concentration in cell lysates.
In vitro angiogenesis test
In vitro angiogenesis was evaluated by seeding HUVE cells on a
3-D collagen gel in a 24-well plate, as previously described (Spisni
et al, 2003), and transfecting them with siRNAs. Briefly, collagen
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sgel was prepared by adding eight volumes of collagen solution
(3mgml
 1, Roche Applied Science, USA) to two volumes of a
mixture containing M199 5 , HEPES 0.02 M and NaHCO3
7.5mgml
 1. After pH adjusting to 7.2–7.4, the mixture was
quickly dispensed to the wells and gelification was achieved at
371C. After gelification, wells were washed twice with M199.
Human endothelial cells (5 10
4well
 1) were seeded onto the gels
and then transfected with siRNAs (final concentration 200pM)b y
using Oligofectamine reagent (Invitrogen, USA) according to the
manufacturer’s instructions. In vitro capillary-like formation was
stimulated with 40nM PMA, examined 48h after transfection by
using a phase contrast microscope and the number of tubular
capillary-like structures per well was counted.
Cloning anti-COX-2 shRNA into pSUPER retroviral vector
Constructs, coding for anti-COX-2 shRNA, were prepared as
described by Brummelkamp et al (2002a). pSUPER.retro vector
(Oligoengine, Seattle, WA, USA), based on the murine stem cell
virus (MSCV) genome, was a kind gift of Dr P Chieco (CRBA lab,
Bologna, Italy). Forward and reverse sequences for anti-COX-2
shRNA construct were 50-gatccccaactgctcaacaccggaatttcaaga
gaattccggtgttgagcagtttttttggaa-30 and 50-agcttttccaaaaaaactgctcaa
caccggaattctcttgaaattccggtgttgagcagttggg-30, respectively, as shown
in Figure 1. 64nt-containing oligos were synthesised and
purchased from PROLIGO (USA). Sequence design started from
the most effective anti-COX-2 synthetic siRNA (sequence B). Steps
for cloning oligonucleotides into pSUPER.retro vector were made
accordingly to pSUPER RNAi system protocol (www.oligoengine.
com). Forward and reverse oligonucleotides were annealed to form
a duplex. The annealed oligos were then ligated into the BglII–
HindIII cleavage site within the pSUPER.retro vector prelinearised
with the same restriction enzymes. Recombinant vector containing
inserts was transformed into competent Escherichia coli cells. After
selection in ampicillin-containing medium, colonies were recov-
ered and checked for the presence of recombinant pSUPER.retro
vector.
Virus production and cell infections
Anti-COX-2 pSUPER.retro. vector was transfected into Phi-NX
(‘Phoenix’) packaging cell line kindly provided by Dr P Chieco
(CRBA lab, Bologna, Italy) to produce ecotropic retroviral
supernatants. Phoenix cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FCS and
pretreated with Chloroquine at final concentration of 25mM. The
day before transfection, Phoenix cells were seeded in 10cm dishes
(3 10
6 cellsdish
 1) in order to reach 60% confluence at the time
of transfection. Cells were transfected with 10mg of viral vector
DNA by using calcium–phosphate precipitation method (Wigler
et al, 1977; Chen and Okayama, 1987). At 48h after transfection,
culture medium was filtered through a 0.45mm filter and the viral
supernatant was used for HT29 cells infection after addition of
8mgml
 1 of polybrene (Sigma, USA). After infection, HT29 cells
were incubated at 321Ci n5 %C O 2 for 6h. Then medium was
changed with fresh medium and HT29 cells were allowed to
recover for 48h at 371Ci n5 %C O 2. Infection efficiency was
examined under a fluorescence microscope to check the green
fluorescent protein (GFP) expression. Infected cells were selected
by adding puromycin (1mgml
 1) for 48h to the culture medium.
Cyclooxygenase-2 expression in HT29 wild-type cells and in HT29
pSUPER(þ) clones (producing anti-COX-2 shRNA) was analysed
by Western blot and by real-time polymerase chain reaction (RT-
PCR), as described in this section. The same procedure was used to
infect HUVE, HCA7 and HeLa cells and to obtain HT29
pSUPER( ) clones infected with empty vector, not expressing
anti-COX-2 shRNA. Infection efficiencies were evaluated by using
confocal microscopy analysis.
Real-time polymerase chain reaction
Total RNA was purified starting from subconfluent HT29 cells
(wild type and pSUPER(þ)) by using Eurozol reagent (CELBIO,
Milan, Italy) according to the manufacturer’s instructions. Total
RNA was quantified by spectrophotometry and analysed by
electrophoresis on 1% agarose/formaldehyde denaturing gel to
exclude the presence of RNA degradation. Extracted total RNA
samples were then treated with DNase I, to remove any genomic
DNA contamination, by using DNA-free kit (Ambion, USA).
mRNA levels were analysed by real-time PCR by using a Bio-Rad
iCycler system (Bio-Rad, USA) according to the manufacturer’s
instructions. Cyclooxygenase-2 mRNA expression was evaluated in
both HT29 wild-type and HT29 pSUPER(þ) cells. The specific
primer pair for COX-2 was designed by using Beacon Designer 2.0
software. The homology with other human sequences and the
formation of template secondary structures were carefully avoided.
Cyclooxygenase-2 primers had the following sequences:
50cctgtgcctgatgattgc3 (forward) and 5ctgatgcgtgaagtgctg3 (reverse).
The primer pair for the housekeeping b-glucuronidase (GUSB)
gene had the following sequences: 50tggtataagaagtatcagaagcc30
(forward) and 50gtatctctctcgcaaaaggaac30 (reverse). Cellular total
RNA was reverse-transcripted into cDNAs and then amplified
by using a SYBR supermix kit (Bio-Rad, USA) for 40 cycles
at 951C for 30s, 531C for 20s and 721C for 30s. The melting curve
data were collected to check PCR specificity. Each cDNA sample
was analysed as triplicate and corresponding samples with no
cDNAs were included as negative controls. Cyclooxygenase-2
mRNA levels for each sample were normalised against GUSB
mRNA levels and relative expressions were calculated by using Ct
values.
(BglII)
Sense sequence Antisense sequence
(loop)
anti-COX2 shRNA
pSUPER.retro+GFP
3′ ∆LTR
5′ LTR
AmpR
Ori
H1
Ψ PGK
GFP
PurR
(HindIII)
5′
5′ 3′
3′
Figure 1 Scheme of pSUPER.retro vector. A specific sequence for anti-
COX-2 short hairpin-RNA (sense sequence – loop – antisense sequence)
was cloned into pSUPER.retro vector and the transcription of this sequence
is regulated by H1 promoter for RNA pol-III. GFP gene expression provides
a rapid test for infection efficiency and the gene for puromycin resistance is
necessary to select clones expressing shRNAs against COX-2 mRNA. All
cassettes are included into retroviral 50–30 LTRs to allow provirus
integration in host cells genome. 30 LTR is inactivated by deletion to avoid
virus replication inside infected cells (see details under Materials And
Methods).
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sMTT assay
HT29 cells (wild type, pSUPER( ) and pSUPER(þ)) were seeded
in 24-well plates (1 10
4cellswell
 1) and the MTT assay was
performed in triplicate at days 2, 5, 8, 12, 15 and 20. Briefly,
medium was replaced with fresh complete medium (450ml). A
measure of 50ml of PBS containing 5mgml
 1 MTT (Sigma, USA)
was added to each well. In the absence of light, samples were
incubated for 2h and precipitates were resuspended by adding
100ml of 10% SDS solution to each well. Absorbance was measured
spectrophotometrically on a plate reader (Bio-Rad, USA) at
570nm.
BrdU labelling index
The cell cycle distribution of HT29 cells (wild type, pSUPER( )
and pSUPER(þ)) was evaluated by using a cytofluorimeter, as
previously described (Landuzzi et al, 2000). Briefly, 1 10
6 cells
were seeded in complete medium. After 24h from seeding, cell
cultures were incubated with 10mM BrdU (Sigma, USA) for 1h in a
CO2 atmosphere at 371C. Harvested cells were fixed in 70% ethanol
for 30min. After DNA denaturation with 2 N HCl for 30min at
room temperature, cells were washed with 0.1 M Na2B4O7 (pH 8.5).
Cells were then processed for indirect immunofluorescence
staining, using a-BrdU (Becton Dickinson, Milan, Italy) diluted
1:4 as a primary MAb, and stained with 20mgml
 1 propidium
iodide before flow cytometry analysis (FACSCalibur, Becton
Dickinson, Milan, Italy).
Cell migration assay
Migration assay was performed by using Boyden chambers (New
Technologies Group, Italy) with 8-mm pore polycarbonate
membranes (New Technologies Group, Italy). Membranes were
coated with Matrigel (Sigma, USA) at 40-fold dilution. Assay was
performed using fresh DMEM supplemented with 10% heat-
inactivated FCS as chemoattractant agent. HT29 cells (wild type,
pSUPER( ) and pSUPER(þ)) were added into the upper chamber
at high density (500 10
3 cells) either in the absence or presence
of PMA 40nM stimulation and then incubated for 24h at 371C.
Following incubation, membranes were disassembled and non-
migratory cells on the upper surface of the membrane were wiped
with a cotton swab. Cell invasion was determined by counting
under light microscopy the number per optical fields ( 200
magnification) of the cells that migrated to the lower side of each
membrane, after fixing and staining membranes with 2%
Toluidine Blue.
Soft-agar colony formation assay
Anchorage-independent growth was determined in 0.33% agarose
(SeaPlaque, FMC BioProducts Rockland, ME, USA), as described
by Benini et al (2004). HT29 cell suspensions (wild type,
pSUPER( ) and pSUPER(þ); 1000 cellssample
 1) were plated
in a semisolid medium (DMEM supplemented with 10% FCS and
0.5% agar). Dishes were incubated at 371C in a humidified
atmosphere containing 5% CO2 and colonies were counted (under
light microscopy) after 7 days.
Confocal microscopy and immunofluorescence analysis
To visualise the localisation of phospho-STAT-1 (Tyr701) protein,
HUVE and HT29 cells were grown on cover slides, washed in TBS
buffer, fixed with 4% paraformaldehyde, permeabilised with PBS-
Triton X-100 0.1% and quenched with cold 0.1% sodium
borohydride in TBS. Cells were treated with blocking buffer (PBS
containing 10% horse serum and 1% BSA) and then incubated with
phospho-STAT-1 (Tyr701) primary antibody diluted 1:100 in TBS-
BSA 1%. After washings, cells were incubated with secondary anti-
rabbit TRITC-conjugated antibody (Dako, Denmark) diluted 1:50
in TBS-BSA 1%. Finally, slides were washed and mounted in
glycerol-PBS medium containing 50mgml
 1 DABCO. To evaluate
pSUPER.retro infection system efficiency, cells (HUVE, HT29,
HCA7 and HeLa) were seeded on cover slides 24h after infection,
fixed with 4% paraformaldehyde and permeabilised with PBS-
Triton X-100 0.1%. Nuclei were stained with propidium iodide
0.05mgml
 1 and slides were mounted, after washings, in glycerol-
PBS medium containing 50mgml
 1 DABCO. The imaging was
performed on a confocal microscope (Leica, Germany) equipped
with an argon/krypton laser. Optical sections were obtained at
increments of 0.5mm in the Z-axis and were digitised with a
scanning mode format of 512 512 pixels. The image processing
and the volume rendering were performed using the Leica TCS
software.
Statistical analysis
Data were expressed as mean7s.e.m. Differences were analysed by
Student’s t-test and considered statistically significant at Po0.05
and Po0.01.
RESULTS
Considering the relevance of endothelial COX-2 in the angiogenic
process, we used an in vitro angiogenesis experimental model,
based on primary HUVEC, to detect whether siRNA molecules
were capable of downregulating COX-2 expression and inhibiting
COX-2-dependent angiogenesis. Four different siRNAs, directed
against COX-2 mRNA, were transfected at 200pM concentration,
by using the Oligofectamine reagent, in HUVEC treated with PMA
to enhance COX-2 expression. As shown in Figure 2, only two
siRNAs (sequences B and C) were capable of reducing COX-2
protein levels by more than 50%, whereas a scrambled siRNA, used
as a negative control, was found to be completely devoid of effects.
Moreover, we demonstrated that the transient knockdown
mediated by siRNAs in HUVEC was highly specific since COX-1
expression resulted unaffected (Figure 2A). In samples in which
COX-2 was downregulated, also PGI2 production, evaluated by
ELISA assay, significantly decreased up to more than 40%
(Figure 2B). Thus, we chose siRNA sequence-B to perform an in
vitro angiogenesis test (Figure 3). As reported in the literature (Ilan
et al, 1998), HUVE cells were able to organise into capillary-like
tubular structures when seeded on 3-D collagen gel and stimulated
with PMA (compare PMA-stimulated cells in Figure 3B to control
cells in A). We observed that transfection of siRNA-B in HUVEC
strongly affected their ability to organise in tubular structures
(Figure 3C), with a significant reduction of vessels number after
PMA stimulation (as shown in Figure 3E). Cells transfected with
scrambled siRNA (Figure 3D) were still able to differentiate in
tubular structures with the same efficiency of PMA-stimulated
control cells (as shown in Figure 3E), allowing to exclude toxicity
and nonspecific effects of siRNA-B on angiogenesis. These results
demonstrate that siRNAs are capable to affect the in vitro
angiogenic process by downregulating COX-2 expression in a
strong specific manner. We also evaluated whether the transfection
of synthetic siRNAs in HUVE cells may activate the interferon-
mediated Jak-STAT pathway, as previously reported for other
siRNAs molecules (Sledz et al, 2003). Western blot analysis of
phospho-STAT-1(Tyr701) (active form) levels, normalised against
p85/p91 STAT-1 total protein levels, showed that only an high
concentration (200nM) of transfected siRNA-B is able to trigger the
interferon system response, whereas a lower but effective dose of
siRNA (200pM) does not have any effect on STAT-1 phosphoryla-
tion (Figure 4A and B). Phorbol 12-myristate 13-acetate-treated
samples were used as positive controls, as suggested by the
Knockdown of cyclooxygenase-2 (COX-2) gene
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sliterature (Cohen et al, 2005). Data from immunofluorescence
analysis were in high agreement with these findings (Figure 4C).
STAT-1 phosphorylation, followed by nuclear translocation, was
strongly increased in samples transfected with siRNA 200nM, while
no relevant differences were detected between samples transfected
with siRNA 200pM and controls. In order to achieve a stable
downregulation of COX-2 in cancer cells, we prepared a
mammalian vector expressing an anti-COX-2 shRNA. We used
the pSUPER.retro vector system, capable of integrating expression
cassettes in human genome, to produce efficient and specific
downregulation of COX-2 gene expression induced by a siRNA
mechanism (Brummelkamp et al, 2002a,b). We cloned the dsRNA
sequence corresponding to siRNA-B into a pSUPER.retro vector
containing also the expression cassette for the GFP. The
recombinant vector was transfected into Phoenix packaging cells
to produce retroviral ecotropic supernatant, used to infect HT29
cells. Infected cells were selected by using standard puromycin
treatment (1mgml
 1) for 48h. Selected HT29 cells (HT29
pSUPER(þ)) were analysed by Western blot for COX-2 expres-
sion. As shown in Figure 5(A and B), COX-2 levels were found to
be significantly decreased (more than 70%) in HT29 pSUPER(þ)
when compared to control cells. The inhibition was still effective
when the COX-2 gene expression was stimulated by PMA
treatment. Cyclooxygenase-2 mRNA levels were analysed in
HT29 pSUPER(þ) by real-time PCR. Results were in strict
accordance with data obtained by Western blot, confirming the
specific COX-2 mRNA degradation by RNAi. In fact, we obtained
an 80% reduction of COX-2 mRNA levels either in the absence or
in the presence of PMA stimulation (Figure 5C). As a further
demonstration of the efficiency of the COX-2 knockdown mediated
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Figure 2 COX-2 specific knockdown by siRNAs in HUVE cells and
evaluation of 6-keto-PGF1a production. HUVE cells were transiently
transfected with siRNAs directed against COX-2 mRNA (sequences A–D;
final concentration 200pM): COX-2 levels (dark bars) and 6-keto-PGF1a
production (bright bars) were analysed by Western blot and ELISA assay,
respectively. All procedures are described under Materials and Methods.
(A) Shows COX-2 and COX-1 expression after siRNAs treatment. After
the evaluation of the bands intensity by Image Master VDS software, both
COX-2 and COX-1 levels were normalised against b-actin expression. All
samples (lanes 2–7) except control in lane 1 were treated with PMA
40nM. Lanes 3–6: samples treated with siRNA A, B, C and D, respectively.
Lane 7: HUVE cells transfected with siRNA-Scr (scrambled), representing a
negative control. Data are expressed as % of PMA-stimulated control value
(lane 2) and represent the mean7s.e.m. of three independent experi-
ments. *(Po0.01); #(Po0.05).
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Figure 3 Small interfering RNA-B (siRNA-B) inhibition of PMA-induced
angiogenesis on 3-D collagen gel. HUVE cells, seeded on 3-D collagen gels,
were transfected with siRNA-B and siRNA-scrambled (C and D
respectively; final concentration 200pM) and treated for 48h with PMA
40nM in order to stimulate the early formation of capillary-like tubular
structures. Results were compared with negative control (no PMA
treatment, A) and PMA-stimulated positive control (B). The graph in (E)
shows the number of capillary structures formed for each sample after
treatments. All procedures are described under Material and Methods and
results are expressed as mean7s.e.m. of three different experiments.
#(Po0.05). Bar: 20mm.
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in HT29 pSUPER(þ) cells (Figure 5D). Since we found, as
mentioned above, that the transfection of exogenous synthetic
siRNAs is capable to activate the interferon system at high
concentrations in HUVE cells, the following aim was to
demonstrate whether an endogenous and constitutive production
12
84 kDa – pSTAT-1
(Tyr701)
STAT-1
PMA – PMA +
C
o
n
t
r
o
l
s
i
R
N
A
-
B
 
2
0
0
 
n
M
s
i
R
N
A
-
B
 
2
0
0
 
p
M
0
PMA
siRNA-B
200 nM
siRNA-B
200 pM
50
100
p
S
T
A
T
-
1
/
S
T
A
T
-
1
(
%
 
o
f
 
c
o
n
t
r
o
l
)
150
200
84 kDa –
34 56
1
**
23456
–
––
––––
+
++
++
– + –
––
+
A
B
C
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Figure 5 Stable knockdown of COX-2 gene by RNAi in HT29 cells. HT29 cells were infected using pSUPER.retro system, selected and analysed for
COX-2 protein and COX-2 mRNA levels by Western blot and real-time PCR (A–C, respectively). PGE2 production (D) was evaluated by using an ELISA
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sof shRNA in the HT29 pSUPER(þ) model had a different effect.
Surprisingly, we found that shRNAs, that strongly downregulate
COX-2 expression in HT29 pSUPER(þ) cells, did not trigger the
interferon system response in the absence of PMA treatment,
compared to the control. Both Western blot (Figure 6A and B) and
immunofluorescence (Figure 6C) analysis of phospho-STAT-
1(Tyr701) levels and localisation confirmed this evidence. More-
over, in order to obtain more data on the effects of the constitutive
COX-2 downregulation in HT29 pSUPER(þ) cells, we performed
four different assays to evaluate the proliferation profile and the
invasiveness of these clones, compared to two different controls:
HT29 wild-type and HT29 pSUPER( ) cells. HT29 pSUPER( )
cells were selected with puromycin after infection with the
retroviral vector, devoid of the anti-COX-2 shRNA expression
cassette. Although the MTT proliferation assay (Figure 7A) and the
cell cycle distribution analysis (Figure 7B) did not show significant
differences between controls and HT29 pSUPER(þ), data from
migration assay performed with Boyden chambers (Figure 8A and
B) and soft-agar colony formation assay (Figure 8C) suggest that
the stable knockdown of COX-2 gene by RNAi promotes a
significant reduction of the migratory ability as well as a strong
inhibition of colony formation in soft agar in infected pSUPER(þ)
colon cancer cells. Interestingly, the loss of the malignant
behaviour in vitro of pSUPER(þ) HT29 cells did not seem to
depend on an impairment of cell growth, since constitutive
expression of anti-COX-2 shRNA in HT29 cells only
slightly modified their proliferation profile and their cell cycle
distribution, but it derived from a reduction of the ability to
invade the extracellular matrix and to grow in anchorage-
independent manner, which are indexes of an invasive
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Figure 6 Effect of anti-COX-2 shRNA expression on the interferon-
signalling cascade in HT29 pSUPER(þ) cells. An analysis of STAT-1
phosphorylation in HT29 wild-type cells and HT29 cells infected using
pSUPER.retro system was performed by Western blot (A and B) and
immunofluorescence (C) assays, following the procedures described under
Material and Methods. Phospho-STAT-1 (Tyr701) and STAT-1 proteins
expression was analysed by Western blot (A) and pSTAT-1 levels,
normalised with respect to STAT-1 total levels, are reported in (B). Lanes
1 and 2: HT29 wild type. Lanes 3 and 4: HT29 pSUPER(þ). Samples in
lanes 2 and 4 were treated with PMA 40nM. Data are expressed as % of
positive control value in lane 2 and represent the mean7s.e.m. of three
independent experiments. The same samples were analysed in an
immunofluorescence assay to determine the phospho-STAT-1 protein
level and localisation (results are shown in C). *(Po0.01). Bar: 20mm.
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Figure 7 Effect of pSUPER.retro infection system on the viability and the
cell cycle distribution of HT29 cells. Proliferation curves were determined
by the MTT assay (A) and the cell cycle distribution analysis was carried out
on 1 10
6 cellssamples
 1 after 60min of incubation with BrdU (B). All
procedures are described under Material and Methods. Control: HT29
wild-type cells (K and lane 1); pSUPER( ): HT29 cells infected with
vector nonexpressing anti-COX2 shRNA (’ and lane 2); pSUPER(þ):
infected HT29 cells expressing shRNA against COX-2 mRNA (m and lane
3). All data represent the mean of three independent experiments.
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sand aggressive behaviour. In the light of future possible
in vivo applications, we finally tested the efficiency of the
pSUPER.retro infection system on HUVEC and different cancer
cell lines. The infection efficiency on HUVE cells was very low (less
than 5%), even if repeated attempts were performed. In contrast,
HT29 and HCA7 colon cancer cell lines, compared to HeLa cells
(used as positive control), were easily infected showing higher
efficiency levels (Figure 9). The infection efficiency for both HT29
and HCA7 was around 45%, whereas it was around 35% for
HeLa cells.
DISCUSSION
RNAi represents a brand new approach in the field of reverse
genetics, since it is a potent tool capable of silencing genes in a
high, long lasting and selective manner. The understanding of
RNAi mechanism of action has soon disclosed a wide spectrum of
possible applications, either in vitro or in vivo. In the past decade,
many studies have shown that small dsRNA molecules are capable
of downregulating genes with sequence homology and that the
knockdown mediated by RNAi machinery is an ubiquitous
phenomenon in eukaryotic cells. Much of the knowledge regarding
RNAi comes from studies on C. elegans. In this organism, Mello
and co-workers in 1998 demonstrated that microRNAs (miRNAs)
physiologically regulate the expression of genes involved in worm
development (Fire et al, 1998; Tuschl et al, 1999; Elbashir et al,
2001b; Tijsterman et al, 2002). Today, siRNAs and shRNAs are
widely used by researchers to silence the expression of many target
genes, because of their high specificity and their apparent
nontoxicity. Moreover, systems based on DNA plasmids or
retroviral vectors have provided new solutions to achieve a stable
knockdown mediated by shRNAs.
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Figure 8 Effect of pSUPER.retro infection system on migration and soft-agar colony formation in HT29 cells. The migration assay was performed by using
Boyden chambers and 8-mm polycarbonate membranes coated with Matrigel (40-fold dilution). After 24h of incubation, cells that migrated through the
Matrigel-coated membranes were fixed, stained, photographed (A) and counted under light microscopy (B). Regarding the soft-agar colony formation assay,
the number of colonies was evaluated 7 days after the seeding in soft agar (C). Control: HT29 wild-type cells; pSUPER( ): HT29 cells infected with vector
nonexpressing anti-COX2 shRNA; pSUPER(þ): infected HT29 cells expressing shRNA against COX-2 mRNA. In the migration assay samples were tested
in the absence and presence of PMA 40nM. All procedures are described under Material and Methods and data in (B) and (C) represent the mean7s.e.m.
of three independent experiments. *(Po0.01); #(Po0.05). Bar: 20mm.
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Figure 9 Efficiency of pSUPER.retro infection system. The images
represent four different cell types that underwent the infection by
pSUPER.retro system (A: HUVEC; B: HT29; C: HCA7; D: HeLa). Cells
were fixed 24h after infection and observed by using confocal microscopy.
Nuclei were stained with propidium iodide and the infected cells appear
GFP-positive since the pSUPER.retro vector contains an expressing cassette
for GFP gene. Bar: 20mm.
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sIn this work, we used a RNAi-based approach to obtain an
efficient knockdown of COX-2 mRNA. The overexpression of
COX-2 seems to play a critical role in many pathological processes.
In particular, the concept that high levels of PGI2 and PGE2, the
main products of arachidonate metabolism in vascular tissues and
cancer cells, respectively, stimulate both tumour-induced angio-
genesis and tumour progression is widely accepted (Leahy et al,
2002; In ˜iguez et al, 2003), whereas the overexpression of the
inducible form of COX enzyme in colorectal cancer cells seems to
promote tumour invasion, tumour growth and tumour metastasis
(Gupta and Dubois, 2001; Yamauchi et al, 2002; Romano and
Claria, 2003; Tuynman et al, 2004). Moreover, the possibility that
the overexpression of genes implicated in human cancers may be
due to a downregulation or a general imbalance of specific
miRNAs has been recently supported (Michael et al, 2003; Calin
et al, 2004; He et al, 2005; Lu et al, 2005) and it could be
investigated in the case of colorectal cancer.
In our experiments, we tested the effect of the transfection of
four different sequences of anti-COX-2 siRNAs on HUVE cells,
stimulated with PMA in order to overexpress COX-2 mRNA. It has
been previously shown that PMA stimulates COX-2 expression in
HUVEC, strongly increasing both mRNA and protein levels (Hirai
et al, 1999). Under these conditions, the release of prostacyclin
(PGI2) was also found to be highly augmented. It is well known
that PGI2 stimulates angiogenesis, probably by acting on a nuclear
receptor belonging to peroxisome proliferator-activated receptors
(PPARs) family (Spisni et al, 2001; Pola et al, 2004). Two of the
synthetic siRNAs tested (sequences B and C) resulted to be
effective in downregulating COX-2 levels and enzymatic activity in
HUVE cells in a specific manner, having no effect on COX-1
expression. Moreover, COX-2 silencing by siRNAs was observed
even at very low concentrations (200pM). Has to be mentioned that
one of these active siRNA sequences (sequence B) overlaps the
same sequence used by Denkert et al (2003) to efficiently
downregulate COX-2 expression in ovarian carcinoma cells. As a
consequence of COX-2 downregulation and PGI2 reduction,
endothelial cells transfected with siRNA-B failed to organise
capillary-like tubular structures in 3-D collagen gel when
stimulated with PMA, whereas control cells (nontransfected or
transfected with a scrambled siRNA) rapidly formed several
lengthened structures sprouting inside the gel.
It has been reported that synthetic siRNAs (Sledz et al, 2003;
Kim et al, 2004; Judge et al, 2005), as well as short single-stranded
RNAs (ssRNAs) (Kim et al, 2004) and some DNA vectors
expressing shRNAs (Bridge et al, 2003), are able to trigger an
interferon response in vitro. On the contrary, other findings
demonstrate that is even possible to administer naked, synthetic
siRNA to mice without inducing any interferon response (Heidel
et al, 2004). In our experimental model, we analysed the
phosphorylation status (on Tyr701) of STAT-1 protein as a marker
of the interferon system activation (Brierley and Fish, 2005). As
STAT-1 activation can be triggered by PMA treatment (Cohen
et al, 2005), we compared the levels of STAT-1 phosphorylated
isoform in HUVEC transfected with siRNA-B at two different doses
(200nM and 200pM) with respect to PMA-stimulated control cells.
While the treatment with a 200nM dose of siRNA-B significantly
increased STAT-1 phosphorylation levels, both in the absence or in
the presence of PMA, the treatment with the same siRNA molecule
at a low dose (200pM) did not show any significant effect on STAT-
1 phosphorylation when compared with controls. Similar results
were obtained by analysing phospho-STAT-1 expression and its
nuclear translocation by immunofluorescence assay, indicating
that low but effective doses of anti-COX-2 siRNA are devoid of
effects on the interferon system.
Following the detection of a siRNA sequence able to efficiently
interfere with COX-2 expression in HUVE cells, we focused our
attention on a new RNAi strategy based on the use of a shRNA-
expressing vector. Our aim was to obtain a stable and efficient
knockdown of COX-2 gene in HT29 cells, a cell line derived from a
human colorectal cancer and known to overexpress this enzyme.
The approach we chose was based on pSUPER.retro technology
(Brummelkamp et al, 2002a,b). Many advantages came from this
approach, first of all the possibility to achieve, by using
inexpensive tools, a potent silencing of target genes that is also
highly specific and long lasting. Therefore, interesting results were
achieved, since data from Western blot, real-time PCR analysis and
ELISA assay clearly showed a strong and selective reduction of
COX-2 protein and mRNA levels, with consequent inhibition of
PGE2 production, in HT29 cells infected with a pSUPER.retro
vector expressing anti-COX-2 siRNA-B (HT29 pSUPER(þ)), even
in the presence of PMA-induced COX-2 overexpression. These
data support the evidence of a strong and long-lasting COX-2
mRNA degradation driven by siRNA molecules processed from
shRNA precursors.
As previously tested in HUVEC treated with anti-COX-2 siRNA-
B, we analysed the effect of the permanent expression of shRNA
molecules on STAT-1 activation in HT29 pSUPER(þ) cells,
detecting no significant increase neither in STAT-1 phosphoryla-
tion levels nor in phospho-STAT-1 nuclear accumulation. These
data suggest that a vector-based stable expression of shRNA
molecules induces a weaker interferon system response with
respect to the transfection of synthetic siRNAs.
Performing experiments aimed to analyse the phenotype of
COX-2-deficient HT29 pSUPER(þ) cells, we detected no sig-
nificant effects of COX-2 downregulation on cell proliferation and
cell cycle distribution, observing only a slight decrease of the
proliferation rate and a slight accumulation of cells in the G0/G1
phase. These results are in line with other data recently collected in
a model of ovarian carcinoma cells (Denkert et al, 2003) and in a
model of human hepatocellular carcinoma cells (Park et al, 2005)
based on siRNA-mediated COX-2 downregulation, suggesting that
COX-2 itself is not decisively involved in the proliferation of
human cancer cells as well.
However, we obtained interesting results by testing the in vitro
invasive behaviour of HT29 pSUPER(þ) cells and their ancho-
rage-independent growth ability. Phorbol 12-myristate 13-acetate-
stimulated HT29 cells, expressing high levels of COX-2, resulted to
be able to degrade and migrate through ECM components of
Matrigel-coated membranes, which indicates their malignant
behaviour in vitro, associated with a well-described invasive and
metastatic ability in vivo (Chen et al, 2001; Kakiuchi et al, 2002).
Moreover, HT29 wild-type cells easily formed colonies in soft agar,
which is an accepted criterion for transformation (Aaronson and
Todaro, 1968) and an experimental condition that better
represents tumour cells growth and invasiveness in vivo (Lawlor
et al, 2002). The knockdown of COX-2 enzyme in HT29 cells
abrogated their ability to invade Matrigel-coated membranes in a
Boyden chamber assay, either in the absence or in the presence of
PMA-stimulation, and strongly impaired their anchorage-
independent growth in soft-agar basal conditions. These results
support the involvement of COX-2 in the malignant behaviour of
human colon carcinoma cells and underline the relevance of a
stable virus-based COX-2 knockdown mediated by RNAi in order
to impair the invasive and metastatic ability of CRC.
Our study confirms the predominant role that RNAi is assuming
in the field of gene silencing owing to its high efficacy, specificity
and nontoxicity. One of the novel targets in cancer therapies is to
obtain a selective downregulation of those genes overexpressed in
tumour tissues. Cyclooxygenase-2 is certainly one of them. Results
reported here indicate an easy-to-use, powerful and high selective
virus-based method to knockdown COX-2 gene in a stable and
long-lasting manner, in colon cancer cells. Furthermore, they open
up the possibility of an in vivo application of this anti-COX-2
retroviral vector, as therapeutic agent for human cancers over-
expressing COX-2. In fact, we observed a significant resistance of
HUVE cells to the pSUPER.retro viral infection in comparison with
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sdifferent types of human cancer cells, either CRC cells (HT29 and
HCA7) and cervix carcinoma cells (HeLa). This observation
indicates that endothelial cells are refractory to retroviral infection
and suggests that this kind of virus-based approach might not
affect the physiological prostaglandins production in vascular
tissues, avoiding some of the well-known side effects coming from
therapies based on selective COX-2 inhibitors (coxibs) (Ray et al,
2002; Fitzegerald, 2004; Horton, 2004; Mamdani et al, 2004;
Oberholzer and Inamdar, 2004; Mitchell and Warner, 2005).
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